Please login to the form below

Not currently logged in
Email:
Password:

Gilead sells rights for cancer drug DaunoXome to Galen

First steps into both the US and the oncology markets for Northern Ireland-based pharma firm

Gilead Sciences has sold the rights for its chemotherapy DaunoXome to Northern Ireland-based Galen Pharmaceuticals.

The acquisition, the value of which remains undisclosed, will be the company's first steps into the both the cancer market and the US.

Previously Galen's focus had been on marketing branded and generic prescription medicines in the UK and Ireland in COPD, urology and pain management.

DaunoXome (daunorubicin citrate liposome injection) is an anthracycline chemotherapy used to treat for advanced HIV-associated Kaposi's sarcoma, a type of cancer that usually affects the skin and mouth, and is caused by human herpes virus 8 (HHV8).

Most people living with the virus don't get Kaposi's sarcoma, however, people with weakened immune systems, such as those living with HIV, are more susceptible to it.

President of Galen Mark Scrutton said: "We are delighted that we are now able to supply DaunoXome in the US for the treatment of patients with this devastating disease.

“DaunoXome marks our first step into the oncology arena and this exciting, new acquisition provides us with the opportunity to offer more widely a much-needed therapy for patients with advanced HIV-associated KS."

As well as the US, Galen will market DaunoXome in 12 European countries and Brazil.

Galen's other products include Flotros for incontinence, Saline Steripoules to nebulise COPD and asthma treatments, and Uracyst to repair damaged bladders.

24th February 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics